Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It has collaboration agreements with Biogen MA, Inc., 4D Molecular Therapeutics, Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation. The company was founded in 1999 and is headquartered in Alachua, Florida.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AGTC
CUSIPN/A
Phone386-462-2204
Debt
Debt-to-Equity RatioN/A
Current Ratio6.61
Quick Ratio6.61
Price-To-Earnings
Trailing P/E Ratio217.50
Forward P/E Ratio-3.66
P/E GrowthN/A
Sales & Book Value
Annual Sales$39.47 million
Price / Sales2.00
Cash Flow$0.0720 per share
Price / Cash60.42
Book Value$6.38 per share
Price / Book0.68
Profitability
EPS (Most Recent Fiscal Year)$0.02
Net Income$400,000.00
Net Margins-65.96%
Return on Equity-16.00%
Return on Assets-13.16%
Miscellaneous
Employees72
Outstanding Shares18,110,000
Applied Genetic Technologies (NASDAQ:AGTC) Frequently Asked Questions
What is Applied Genetic Technologies' stock symbol?
Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."
How were Applied Genetic Technologies' earnings last quarter?
Applied Genetic Technologies Corp (NASDAQ:AGTC) issued its quarterly earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by $0.04. The biotechnology company had revenue of $3.60 million for the quarter, compared to analysts' expectations of $6.41 million. Applied Genetic Technologies had a negative return on equity of 16.00% and a negative net margin of 65.96%. View Applied Genetic Technologies' Earnings History.
When is Applied Genetic Technologies' next earnings date?
What price target have analysts set for AGTC?
5 brokerages have issued 12-month target prices for Applied Genetic Technologies' stock. Their forecasts range from $7.00 to $12.00. On average, they anticipate Applied Genetic Technologies' share price to reach $9.00 in the next year. View Analyst Ratings for Applied Genetic Technologies.
What are Wall Street analysts saying about Applied Genetic Technologies stock?
Here are some recent quotes from research analysts about Applied Genetic Technologies stock:
- 1. According to Zacks Investment Research, "Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. Applied Genetic Technologies Corporation is headquartered in Alachua, Florida. " (3/30/2018)
- 2. Cantor Fitzgerald analysts commented, "Natural history data from imaging 41 patients with CNGB3-associated achromatopsia (ACHM B3) between 6 and 26 months was published in the journel Retina journal today, suggest functional endpoints for evaluating efficacy." (10/6/2017)
Who are some of Applied Genetic Technologies' key competitors?
Some companies that are related to Applied Genetic Technologies include Cellular Biomedicine Group (CBMG), Allena Pharmaceuticals (ALNA), Jounce Therapeutics (JNCE), Agenus (AGEN), Arsanis (ASNS), Nantkwest (NK), ADMA Biologics (ADMA), Compugen (CGEN), Fennec Pharmaceuticals (FENC), Organovo (ONVO), Eiger Biopharmaceuticals (EIGR), Krystal Biotech (KRYS), Pluristem Therapeutics (PSTI), Aptose Biosciences (APTO) and Cidara Therapeutics (CDTX).
Who are Applied Genetic Technologies' key executives?
Applied Genetic Technologies' management team includes the folowing people:
- Ms. Susan B. Washer, Pres, CEO & Director (Age 57)
- Dr. Mark S. Shearman Ph.D., Chief Scientific Officer (Age 58)
- Mr. Stephen W. Potter, VP & Chief Bus. Officer (Age 62)
- Dr. Jeffrey D. Chulay, Exec. Director of Clinical Strategy (Age 71)
- Dr. Nicholas Muzyczka, Co-Founder
Has Applied Genetic Technologies been receiving favorable news coverage?
Media headlines about AGTC stock have been trending somewhat positive on Saturday, according to Accern. Accern ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Applied Genetic Technologies earned a coverage optimism score of 0.13 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 47.24 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are Applied Genetic Technologies' major shareholders?
Applied Genetic Technologies' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (3.49%), BlackRock Inc. (2.12%), Altrinsic Global Advisors LLC (1.36%), Point72 Asset Management L.P. (0.99%), Alambic Investment Management L.P. (0.61%) and ClariVest Asset Management LLC (0.61%). Company insiders that own Applied Genetic Technologies stock include Ivana Magovcevic, Jeffrey D Chulay, Lawrence E Bullock, Mark S Shearman and Stephen W Potter. View Institutional Ownership Trends for Applied Genetic Technologies.
Which institutional investors are selling Applied Genetic Technologies stock?
Which institutional investors are buying Applied Genetic Technologies stock?
AGTC stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Dimensional Fund Advisors LP, Ancora Advisors LLC, Matarin Capital Management LLC, Altrinsic Global Advisors LLC and Alambic Investment Management L.P.. Company insiders that have bought Applied Genetic Technologies stock in the last two years include Ivana Magovcevic, Lawrence E Bullock, Mark S Shearman and Stephen W Potter. View Insider Buying and Selling for Applied Genetic Technologies.
How do I buy shares of Applied Genetic Technologies?
Shares of AGTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Applied Genetic Technologies' stock price today?
One share of AGTC stock can currently be purchased for approximately $4.35.
How big of a company is Applied Genetic Technologies?
Applied Genetic Technologies has a market capitalization of $79.69 million and generates $39.47 million in revenue each year. The biotechnology company earns $400,000.00 in net income (profit) each year or $0.02 on an earnings per share basis. Applied Genetic Technologies employs 72 workers across the globe.
How can I contact Applied Genetic Technologies?
Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The biotechnology company can be reached via phone at 386-462-2204.
MarketBeat Community Rating for Applied Genetic Technologies (AGTC)
MarketBeat's community ratings are surveys of what our community members think about Applied Genetic Technologies and other stocks. Vote "Outperform" if you believe AGTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
